Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guido Marcucci

Showing results (321-330 of 536) with videos related to

Pageof 54
Sort By:
Clinical and Translational Medicine|October 28, 2021
Targeting miR-126 disrupts maintenance of myelodysplastic syndrome stem and progenitor cellsHuafeng Wang, Jie Sun, Bin Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2012
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502Eyal C Attar, Jeffrey L Johnson, Philip C Amrein, et al.
British Journal of Haematology|September 1, 2025
The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemiaHoda Pourhassan, Jose Tinajero, Huiyan Ma, et al.
Blood|August 11, 2011
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemiaSebastian Schwind, Guido Marcucci, Jessica Kohlschmidt, et al.
Blood Advances|January 10, 2019
MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimenHaris Ali, Ibrahim Aldoss, Dongyun Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B studyGuido Marcucci, Krzysztof Mrózek, Amy S Ruppert, et al.
Blood Advances|October 17, 2017
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with <i>FLT3</i>-mutated acute myeloid leukemia: CALGB 11001Geoffrey L Uy, Sumithra J Mandrekar, Kristina Laumann, et al.
Blood|June 2, 2021
Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemiaCaroline Duault, Anil Kumar, Adeleh Taghi Khani, et al.
Cancer|January 3, 2014
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808Jonathan E Kolitz, Stephen L George, Don M Benson, et al.
Bone Marrow Transplantation|June 10, 2021
Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantationStephanie Mac, Dat Ngo, Dongyun Yang, et al.
Pageof 54

Showing results (321-330 of 536) with videos related to

Sort By:
Pageof 54
Clinical and Translational Medicine|October 28, 2021
Targeting miR-126 disrupts maintenance of myelodysplastic syndrome stem and progenitor cellsHuafeng Wang, Jie Sun, Bin Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2012
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502Eyal C Attar, Jeffrey L Johnson, Philip C Amrein, et al.
British Journal of Haematology|September 1, 2025
The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemiaHoda Pourhassan, Jose Tinajero, Huiyan Ma, et al.
Blood|August 11, 2011
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemiaSebastian Schwind, Guido Marcucci, Jessica Kohlschmidt, et al.
Blood Advances|January 10, 2019
MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimenHaris Ali, Ibrahim Aldoss, Dongyun Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B studyGuido Marcucci, Krzysztof Mrózek, Amy S Ruppert, et al.
Blood Advances|October 17, 2017
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with <i>FLT3</i>-mutated acute myeloid leukemia: CALGB 11001Geoffrey L Uy, Sumithra J Mandrekar, Kristina Laumann, et al.
Blood|June 2, 2021
Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemiaCaroline Duault, Anil Kumar, Adeleh Taghi Khani, et al.
Cancer|January 3, 2014
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808Jonathan E Kolitz, Stephen L George, Don M Benson, et al.
Bone Marrow Transplantation|June 10, 2021
Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantationStephanie Mac, Dat Ngo, Dongyun Yang, et al.
Pageof 54